TVG: Robert Kilpatrick introduces BioPartnering Future Europe




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: TVG: Robert Kilpatrick introduces BioPartnering Future Europe
Released on: November 19, 2011. © PharmaTelevision Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
  • Summary
  • Transcript
  • Participants
  • Company
In this episode of PharmaTelevision News Review, Paul Larsmon talks to Robert Kilpatrick, CEO of TVG.
TVG's plan to make Europe globally competitive
Paul Larsmon :
Hello and welcome to PharmaTelevision News Review here at BioPartnering Europe 2011. On the show today I've got Robert Lee Kilpatrick, from TVG the conference organizers, Robert you are leading London after nearly 20-years, have we done something wrong?
Robert Lee Kilpatrick:
Absolutely not, we love London and we love being in the UK our project is to really take BioPartnering Europe, evolve it into something called BioPartnering Future Europe which will encompass all of Europe from Norway to Sicily from Ireland to Russia and in order to do that we have to build relationships with Europeans, we are gonna move around.
Paul Larsmon :
Why do you think people will be happier to come, I know you go to Brussels next year, why do you think people will be happy to go to Brussels rather than here?
Robert Lee Kilpatrick:
Well it's the capital of Europe in many respects and so next year is our 20th anniversary, I don't know if you know this but BioPartnering Europe was founded in 1993 and it was the world's first biopharma partnering event.
Paul Larsmon :
You are going to Brussels next year then what happens after that?
Robert Lee Kilpatrick:
Well we were gonna move around Europe.
Paul Larsmon :
You know take the caravan out there?
Robert Lee Kilpatrick:
Exactly kind of travelling circus and the point is that you talk about a conference but really it's a network of people, so TVG is unique in that we have a global platform, we do the same thing in Brazil, China, India, Australia, USA and Canada so our plan is to bring all of Europe together in one place which currently nobody does and also to bring the rest of the world to Europe to make it more globally competitive.
Colloboration with European Commission and formation of "BioPartnering Future Europe"
Paul Larsmon :
You've talked about BP evolving what do you mean by that, because I mean in many people's eyes you know yes you are right it's a people business but you are putting people in one place and letting them chat, I mean what's going to evolve? How people are gonna notice the difference?
Robert Lee Kilpatrick:
Good question, key to that is the slight name change it's going to be called BioPartnering Future Europe and one of our collaborators is the European Commission and the European Commission has goals for 2020 to help transform Europe into more of a knowledge based economy and the life science is essential to that, so they have specific goals that they've set out for 2020 for us that's about the future, so we put the word future into the name BioPartnering Future Europe saying we intend to be here in the future, we intend to contribute to the project of helping make the region more globally competitive and also I think helping life science drive living standards, extend life to make life for European's fore and also through partnerships with the rest of the world help Europe take many of the advances, patents and the knowledge that's been evolved here and help it improve life's in China, in India and the emerging markets.
Robert 's perspective: Current financing environment in European biotech industry
Paul Larsmon :
You talked about the future what about the present, I mean what state is European biotech in at the moment, tough times I guess?
Robert Lee Kilpatrick:
Awful.
Paul Larsmon :
Where is the awfulness focus there, you used that word awful?
Robert Lee Kilpatrick:
It's awful because it's difficult to raise capital at the moment and so part of the BioPartnering Future Europe concept is by building say a tie with the European Commission we are helping companies access parts of capital that they may not be aware of in the 2020 project, the commission is increasing funding 45% for life sciences in Europe and that's good news for European companies.
Paul Larsmon :
So, I mean do you see more as we go forward do you see more funding coming in from public bodies, from governments rather than perhaps from big pharma?
Robert Lee Kilpatrick:
Absolutely, and here at BioPartnering Europe for example we have the Wellcome Trust, we have other kind of charitable organizations who I think are going to work together with groups like the European Commission or national bodies and pharma companies, but pharma companies are still companies and so they don't have an unlimited capacity to fund the global life science industry, we're gonna have to see more partnerships I think.
Robert 's views: Future of European biotech over next 5 years
Paul Larsmon :
Looking forward then 5, 10 years even how do you think European biotech in particular is going to develop?
Robert Lee Kilpatrick:
I think at least two or three things will happen, firstly I think there will continue to be kind of a consolidation, so many of the smaller companies will be acquired or they will merge within Europe and I think one of the goals of BioPartnering Future Europe is to help accelerate the process of creating a critical mass of globally competitive companies rather than the present situation where there are 1000's of companies many of them are one product shows and they just don't have the strengths to survive in the global market. Secondly I think European companies will do more deals with overseas firms so you will see more investment in Europe from Asia and from North America, we were in Sao Paulo three weeks ago at BioPartnering Latin America and there is a huge interest in Brazil, in Chile and Argentina in forming ties with the European companies there is a lot of money in Russia now that's being air marked for life science and of course we have the almost bottomless pit of cash in the Middle East Qatar and Kuwait and places they wanna continue to diversify their portfolio's and I think life science will be attractive. And I think lastly, I do think that big pharma is getting into the venture world more they are forming venture arms and I think you're going to see more direct investments from Novartis, and Roche, and GSK and people like that in smaller companies.
Paul Larsmon :
You mentioned Russia, can you say a day when BP might be held in Moscow?
Robert Lee Kilpatrick:
Sure, absolutely.
Paul Larsmon :
Robert, thanks very much for joining us.
Robert Lee Kilpatrick:
Thank you.
Paul Larsmon
Paul Larsmon has worked as a broadcast television journalist for 25 years, covering general news, business and politics. He has been both presenter and producer in several news broadcasters, including the major British television news company ITN. He joined PharmaTelevision as Executive Producer earlier this year and has been responsible for getting , PTV News launched.
Robert Lee Kilpatrick
Co-Founder and Partner
Robert Lee Kilpatrick is Co-Founder and Partner of Technology Vision Group LLC (TVG). Since 1992, Dr. Kilpatrick along with TVG has been connecting innovators and leaders in the life science industry across the US, Canada, China, Europe, Australia, Latin America, India, and Asia. The 18-year track record of success is founded by a deep industry knowledge, integrity in business, and powerful network of valuable relationships - fulfilling the vision to be Your Global Life Science Network". Dr. Kilpatrick was educated at the University of California Berkeley and Cambridge University, where he received a Doctorate in the History and Philosophy of Science and Medicine. He is on the Board of Directors of the BayBio Institute, a non-profit think tank in San Francisco focused on issues related to the bio-economy. Professional memberships include: BayBio Life Science Assoc, BIOTECanada, and the Biotechnology Industry Organization (BIO).
PharmaVentures
PharmaVentures is a company that has proven success in deals and alliances. PharmaVentures offers: Over 18 years of healthcare industry experience gained from working with in excess of 1000 clients in 38 countries, and conducting more than 450 assignments Over 40 specialist advisors, analysts and researchers Skills honed in many countries - 80% of its business comes from outside the UK.
Technology Vision Group LLC (TVG)
Technology Vision Group LLC (TVG): Since 1992, TVG has been connecting innovators and leaders in the life science industry across the US, Canada, China, Europe, Australia, Latin America, India, and Asia. TVG enables a global network that supports life science companies as they build new relationships, enter new markets, and create new products. TVG's 19-year track record (1992-2011) of success is founded on its deep industry knowledge, integrity in business, and powerful network of valuable relationships. TVG are judged by the company they keep and have helped over 3,200 life science companies achieve their business goals. TVG continues to expand their network into new markets in Latin America, China, and India fulfilling vision to be "Your Global Life Science Network".